FogPharma and Artbio Collab on Alpha-Particle Radioligand Therapies
FogPharma and ARTBIO have joined forces to develop a groundbreaking class of radioligand therapies (ARTs) that harness the power...
Adaptive Clinical Trial Design Adaptive Trial Design AI in Clinical Trials alcohol use disorder Alzheimer's Disease Article Clinical Operations Clinical Research Clinical Trial Design Clinical Trial Operations Clinical Trial Ops Brief Clinical Trials CLINOPS WATCHDOG CNS Drug Development CNS Trials Conference Coverage Decentralized Clinical Trials Digital Health Technologies DOGE FDA Budget Cuts eClinical Tech News eClinical Technology EMA Executive Interviews FDA Enforcement FDA Guidance FDA Real-World Evidence FDA Regulation FDA Regulatory Authority FDA Regulatory Strategy GCP Compliance GLP-1 Receptor Agonists Ketamine Therapy Oncology Trials Opinion Parkinson's Disease Platform Trials Protocol Design Psilocybin MDMA Psychedelic Clinical Trials PSYCH PULSE Real-World Evidence site activation Site Operations study startup Treatment-Resistant Depression
FogPharma and ARTBIO have joined forces to develop a groundbreaking class of radioligand therapies (ARTs) that harness the power...
Oncodesign Precision Medicine (OPM) and Navigo Proteins GmbH have partnered to develop radiotheranostics, a targeted therapy that delivers radioactivity...
Bristol Myers Squibb’s Breyanzi has received accelerated FDA approval for adult patients with relapsed or refractory follicular lymphoma who...
Moffitt Cancer Center and Fulgent Pharma have formed a partnership to accelerate the development of personalized cancer therapies. •...
Syros Pharmaceuticals focused on hematologic malignancies and provided updates on its clinical progress, including the passing of the interim...
Alto Neuroscience has initiated a Phase 2 study of ALTO-203, a PDE4 inhibitor targeted at patients with major depressive...
Medidata, a leading clinical trial solutions provider, has partnered with Worldwide Clinical Trials (Worldwide) to leverage Medidata AI. This...
Oklo Inc., a provider of clean nuclear power and fuel recycling, has partnered with Atomic Alchemy Inc. to meet...
In this interview, Dr. Ping Cao, co-founder and CEO of BridGene Biosciences, discusses targeting “hard to drug” proteins that...
Empatica, a digital biomarker development and patient monitoring company, has integrated McRoberts’ 71 endpoints into its FDA-cleared Health Monitoring...